A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study

Clinical Therapeutics

Volumn 26, Issue 6, 2004, Pages 878-888

  Mizuno, Kyoichi ^a,h   Nakamura, Haruo ^b   Ohashi, Yasuo ^c   Kaburagi, Tsuneo ^d   Kitabatake, Akira ^e   Tochihara, Toshihiko ^f   Hosoda, Saichi ^g  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Mitsukoshi Health and Welfare Foundation   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d Kaburagi Medical Clinic   (Japan)

^e HOKKAIDO UNIVERSITY   (Japan)

^f SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^g SAKAKIBARA HEART INSTITUTE   (Japan)

^h NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

coronary atherosclerosis; hypercholesterolemia; quantitative coronary angiography; simvastatin

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIET THERAPY; DISEASE COURSE; DRUG UTILIZATION; FEMALE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STENOSIS;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DIET; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; JAPAN; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 3242715180     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90131-2     Document Type: Article

References (29)

1. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 323:1990;1289-1298
2. Blankenhorn D.H., Azen S.P., Kramsch D.M., et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med. 119:1993;969-976
3. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet. 344:1994;633-638
4. published correction appears in Lancet. 344:1994;762
5. Pitt B., Mancini G.B., Ellis S.G., et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol. 26:1995;1133-1139
6. Waters D., Higginson L., Gladstone P., et al., Canadian Coronary Atherosclerosis Intervention Trial. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation. 89:1994;959-968
7. Watts G.F., Lewis B., Brunt J.N., et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Athertosclerosis Regression Study (STARS). Lancet. 339:1992;563-569
8. Jukema J.W., Bruschke A.V., van Boven A.J., et al., Regression Growth Evaluation Statin Study (REGRESS). Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation. 91:1995;2528-2540
9. Sacks F.M., Pasternak R.C., Gibson C.M., et al. Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet. 344:1994;1182-1186
10. Herd J.A., Ballantyne C.M., Farmer J.A., et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]. Am J Cardiol. 80:1997;278-286
11. Mack W.J., Xiang M., Selzer R.H., Hodis H.N. Serial quantitative coronary angiography and coronary events. Am Heart J. 139:2000;993-999
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 360:2002;7-22
13. Itakura H., Goto Y., Oikawa S., et al. Clinical study of MK-733 (simvastatin)-dose range finding study. [in Japanese] Rinsho-Iyaku. 5:1989;2011-2040
14. Austen W.G., Edwards J.E., Frye R.L., et al. A reporting system on patients evaluated for coronary artery disease: Report of the Ad Hoc Committee for Grading of CAD, Council on Cardiovascular Surgery, American Heart Association. Circulation. 51:(Suppl 4):1975;5-40
15. de Feyter P.J., Serruys P.W., Davies M.J., et al. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations, and implications for clinical trials. Circulation. 84:1991;412-423
16. Reiber J.H., Serruys P.W., Kooijman C.J., et al. Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation. 71:1985;280-288
17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389
18. Sacks F.M., Pfeffer M.A., Moye L.A., et al., Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009
19. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357
20. Downs J.R., Clearfield M., Weis S., et al., Air Force/Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622
21. Teo K.K., Burton J.R., Buller C.E., et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 102:2000;1748-1754
22. Bestehorn H.P., Rensing U.F., Roskamm H., et al., Multicenter Coronary Intervention Study (CIS). The effect of simvastatin on progression of coronary artery disease. Eur Heart J. 18:1997;226-234
23. Rubin E.M., Krauss R.M., Spangler E.A., et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:1991;265-267
24. Ballantyne C.M., Herd J.A., Dunn J.K., et al. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol. 8:1997;354-361
25. Rossouw J.E. Lipid-lowering interventions in angiographic trials. Am J Cardiol. 76:1995;86C-92C
26. Waters D., Craven T.E., Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 87:1993;1067-1075
27. Keys A., Menotti A., Aravanis C., et al. The seven countries study: 2,289 deaths in 15 years. Prev Med. 13:1984;141-154
28. Sekikawa A., Sato T., Hayakawa T., et al. Coronary heart disease mortality among men aged 35-44 years by prefecture in Japan in 1995-1999 compared with that among white men aged 35-44 by state in the United States in 1995-1998: Vital statistics data in recent birth cohort. Jpn Circ J. 65:2001;887-892
29. Kodama K., Sasaki H., Shimizu Y. Trend of coronary heart disease and its relationship to risk factors in a Japanese population: A 26-year follow-up, Hiroshima/Nagasaki study. Jpn Circ J. 54:1990;414-421